BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17900801)

  • 1. AG490 influences UCN-01-induced cytotoxicity in glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation.
    Jane EP; Premkumar DR; Pollack IF
    Cancer Lett; 2007 Nov; 257(1):36-46. PubMed ID: 17900801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status.
    Husain A; Yan XJ; Rosales N; Aghajanian C; Schwartz GK; Spriggs DR
    Clin Cancer Res; 1997 Nov; 3(11):2089-97. PubMed ID: 9815601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.
    Wang Q; Fan S; Eastman A; Worland PJ; Sausville EA; O'Connor PM
    J Natl Cancer Inst; 1996 Jul; 88(14):956-65. PubMed ID: 8667426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation.
    Sugiyama K; Shimizu M; Akiyama T; Tamaoki T; Yamaguchi K; Takahashi R; Eastman A; Akinaga S
    Int J Cancer; 2000 Mar; 85(5):703-9. PubMed ID: 10699952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
    Tse AN; Schwartz GK
    Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
    Nguyen D; Zajac-Kaye M; Rubinstein L; Voeller D; Tomaszewski JE; Kummar S; Chen AP; Pommier Y; Doroshow JH; Yang SX
    Cell Cycle; 2011 Dec; 10(23):4074-82. PubMed ID: 22101337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function.
    Shao RG; Cao CX; Shimizu T; O'Connor PM; Kohn KW; Pommier Y
    Cancer Res; 1997 Sep; 57(18):4029-35. PubMed ID: 9307289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01.
    Eastman A; Kohn EA; Brown MK; Rathman J; Livingstone M; Blank DH; Gribble GW
    Mol Cancer Ther; 2002 Oct; 1(12):1067-78. PubMed ID: 12481430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing CHK1 inhibitor lethality in glioblastoma.
    Tang Y; Dai Y; Grant S; Dent P
    Cancer Biol Ther; 2012 Apr; 13(6):379-88. PubMed ID: 22313687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of p53 in growth arrest and apoptosis on combined treatment of human Mammary epithelial cells with topotecan and UCN-01.
    Redkar A; Mixter P; Daoud SS
    J Exp Ther Oncol; 2004 Oct; 4(3):213-22. PubMed ID: 15724841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.
    Dasmahapatra GP; Didolkar P; Alley MC; Ghosh S; Sausville EA; Roy KK
    Clin Cancer Res; 2004 Aug; 10(15):5242-52. PubMed ID: 15297428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
    Hirose Y; Berger MS; Pieper RO
    Cancer Res; 2001 Aug; 61(15):5843-9. PubMed ID: 11479224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
    Yu Q; La Rose J; Zhang H; Takemura H; Kohn KW; Pommier Y
    Cancer Res; 2002 Oct; 62(20):5743-8. PubMed ID: 12384533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma.
    Mack PC; Gandara DR; Lau AH; Lara PN; Edelman MJ; Gumerlock PH
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):337-48. PubMed ID: 12721762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.
    Levesque AA; Fanous AA; Poh A; Eastman A
    Mol Cancer Ther; 2008 Feb; 7(2):252-62. PubMed ID: 18281511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined antitumor activity of 7-hydroxystaurosporine (UCN-01) and tamoxifen against human breast carcinoma in vitro and in vivo.
    Koh J; Kubota T; Koyama T; Migita T; Hashimoto M; Hosoda Y; Kitajima M
    Breast Cancer; 2003; 10(3):260-7. PubMed ID: 12955040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
    Tentori L; Portarena I; Torino F; Scerrati M; Navarra P; Graziani G
    Glia; 2002 Oct; 40(1):44-54. PubMed ID: 12237842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.
    Trepel M; Groscurth P; Malipiero U; Gulbins E; Dichgans J; Weller M
    J Neurooncol; 1998 Aug; 39(1):19-32. PubMed ID: 9760067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of human glioma cell proliferation by altered Bax/Bcl-2-p53 expression and apoptosis induction by Rhaponticum carthamoides extracts from transformed and normal roots.
    Skała E; Sitarek P; Toma M; Szemraj J; Radek M; Nieborowska-Skorska M; Skorski T; Wysokińska H; Śliwiński T
    J Pharm Pharmacol; 2016 Nov; 68(11):1454-1464. PubMed ID: 27696406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma.
    Mack PC; Gandara DR; Bowen C; Edelman MJ; Paglieroni T; Schnier JB; Gelmann EP; Gumerlock PH
    Clin Cancer Res; 1999 Sep; 5(9):2596-604. PubMed ID: 10499638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.